![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RICTOR |
Gene summary for RICTOR |
![]() |
Gene information | Species | Human | Gene symbol | RICTOR | Gene ID | 253260 |
Gene name | RPTOR independent companion of MTOR complex 2 | |
Gene Alias | AVO3 | |
Cytomap | 5p13.1 | |
Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | Q6R327 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
253260 | RICTOR | CA_HPV_1 | Human | Cervix | CC | 2.48e-03 | 1.49e-01 | 0.0264 |
253260 | RICTOR | CCI_1 | Human | Cervix | CC | 8.38e-09 | 1.14e+00 | 0.528 |
253260 | RICTOR | CCI_2 | Human | Cervix | CC | 1.35e-08 | 1.12e+00 | 0.5249 |
253260 | RICTOR | CCI_3 | Human | Cervix | CC | 1.50e-20 | 1.40e+00 | 0.516 |
253260 | RICTOR | sample3 | Human | Cervix | CC | 8.26e-12 | 3.32e-01 | 0.1387 |
253260 | RICTOR | T3 | Human | Cervix | CC | 3.80e-10 | 3.24e-01 | 0.1389 |
253260 | RICTOR | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.45e-15 | -6.11e-01 | 0.0155 |
253260 | RICTOR | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.63e-07 | -5.63e-01 | -0.1207 |
253260 | RICTOR | HTA11_696_2000001011 | Human | Colorectum | AD | 7.53e-13 | -3.94e-01 | -0.1464 |
253260 | RICTOR | HTA11_866_2000001011 | Human | Colorectum | AD | 2.70e-02 | -2.96e-01 | -0.1001 |
253260 | RICTOR | HTA11_546_2000001011 | Human | Colorectum | AD | 3.73e-02 | -4.18e-01 | -0.0842 |
253260 | RICTOR | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.34e-02 | -5.30e-01 | -0.0179 |
253260 | RICTOR | HTA11_866_3004761011 | Human | Colorectum | AD | 3.26e-10 | -4.67e-01 | 0.096 |
253260 | RICTOR | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.99e-05 | -4.33e-01 | 0.0674 |
253260 | RICTOR | HTA11_99999974143_84620 | Human | Colorectum | MSS | 7.06e-23 | -5.55e-01 | 0.3005 |
253260 | RICTOR | F007 | Human | Colorectum | FAP | 1.81e-05 | -4.34e-01 | 0.1176 |
253260 | RICTOR | A002-C-010 | Human | Colorectum | FAP | 2.41e-04 | -1.91e-01 | 0.242 |
253260 | RICTOR | A001-C-207 | Human | Colorectum | FAP | 1.09e-04 | -2.45e-01 | 0.1278 |
253260 | RICTOR | A015-C-203 | Human | Colorectum | FAP | 8.87e-28 | -3.88e-01 | -0.1294 |
253260 | RICTOR | A015-C-204 | Human | Colorectum | FAP | 3.91e-04 | -2.55e-01 | -0.0228 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
GO:00071639 | Cervix | CC | establishment or maintenance of cell polarity | 63/2311 | 218/18723 | 4.25e-11 | 8.76e-09 | 63 |
GO:190290310 | Cervix | CC | regulation of supramolecular fiber organization | 92/2311 | 383/18723 | 1.49e-10 | 2.48e-08 | 92 |
GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
GO:004325410 | Cervix | CC | regulation of protein-containing complex assembly | 96/2311 | 428/18723 | 2.91e-09 | 3.05e-07 | 96 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:011005310 | Cervix | CC | regulation of actin filament organization | 67/2311 | 278/18723 | 4.01e-08 | 2.54e-06 | 67 |
GO:00430877 | Cervix | CC | regulation of GTPase activity | 79/2311 | 348/18723 | 4.21e-08 | 2.60e-06 | 79 |
GO:00300108 | Cervix | CC | establishment of cell polarity | 42/2311 | 143/18723 | 4.30e-08 | 2.62e-06 | 42 |
GO:005125810 | Cervix | CC | protein polymerization | 70/2311 | 297/18723 | 5.20e-08 | 3.11e-06 | 70 |
GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
GO:00506787 | Cervix | CC | regulation of epithelial cell proliferation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
GO:003227110 | Cervix | CC | regulation of protein polymerization | 57/2311 | 233/18723 | 2.37e-07 | 1.03e-05 | 57 |
GO:003133410 | Cervix | CC | positive regulation of protein-containing complex assembly | 55/2311 | 237/18723 | 2.25e-06 | 6.73e-05 | 55 |
GO:190290510 | Cervix | CC | positive regulation of supramolecular fiber organization | 50/2311 | 209/18723 | 2.55e-06 | 7.54e-05 | 50 |
GO:00719007 | Cervix | CC | regulation of protein serine/threonine kinase activity | 75/2311 | 359/18723 | 2.76e-06 | 8.02e-05 | 75 |
GO:00315328 | Cervix | CC | actin cytoskeleton reorganization | 31/2311 | 107/18723 | 3.34e-06 | 8.99e-05 | 31 |
GO:00081549 | Cervix | CC | actin polymerization or depolymerization | 51/2311 | 218/18723 | 4.05e-06 | 1.05e-04 | 51 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa041505 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
hsa0415013 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
hsa041502 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
hsa0415011 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
hsa041504 | Oral cavity | OSCC | mTOR signaling pathway | 90/3704 | 156/8465 | 2.87e-04 | 9.15e-04 | 4.66e-04 | 90 |
hsa0415012 | Oral cavity | OSCC | mTOR signaling pathway | 90/3704 | 156/8465 | 2.87e-04 | 9.15e-04 | 4.66e-04 | 90 |
hsa0415021 | Oral cavity | EOLP | mTOR signaling pathway | 34/1218 | 156/8465 | 7.59e-03 | 2.17e-02 | 1.28e-02 | 34 |
hsa041503 | Oral cavity | EOLP | mTOR signaling pathway | 34/1218 | 156/8465 | 7.59e-03 | 2.17e-02 | 1.28e-02 | 34 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RICTOR | SNV | Missense_Mutation | novel | c.22N>T | p.Arg8Cys | p.R8C | Q6R327 | protein_coding | deleterious(0) | benign(0) | TCGA-DD-AAE4-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
RICTOR | SNV | Missense_Mutation | novel | c.4680A>T | p.Gln1560His | p.Q1560H | Q6R327 | protein_coding | tolerated(0.12) | possibly_damaging(0.471) | TCGA-DD-AAE7-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
RICTOR | SNV | Missense_Mutation | c.3474N>T | p.Gln1158His | p.Q1158H | Q6R327 | protein_coding | tolerated(0.08) | benign(0.127) | TCGA-EP-A2KB-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
RICTOR | SNV | Missense_Mutation | novel | c.1055N>T | p.Ser352Ile | p.S352I | Q6R327 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-05-5425-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | gefitinib | PD |
RICTOR | SNV | Missense_Mutation | c.4330G>T | p.Gly1444Cys | p.G1444C | Q6R327 | protein_coding | tolerated(0.15) | benign(0) | TCGA-44-2656-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
RICTOR | SNV | Missense_Mutation | c.172G>T | p.Gly58Cys | p.G58C | Q6R327 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-44-2656-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
RICTOR | SNV | Missense_Mutation | novel | c.3240N>C | p.Lys1080Asn | p.K1080N | Q6R327 | protein_coding | tolerated(0.06) | probably_damaging(0.994) | TCGA-44-7662-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RICTOR | SNV | Missense_Mutation | c.53N>T | p.Arg18Leu | p.R18L | Q6R327 | protein_coding | deleterious(0) | benign(0.001) | TCGA-44-8120-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
RICTOR | SNV | Missense_Mutation | novel | c.1018N>A | p.Pro340Thr | p.P340T | Q6R327 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-49-4510-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
RICTOR | SNV | Missense_Mutation | rs766067681 | c.3329N>T | p.Arg1110Leu | p.R1110L | Q6R327 | protein_coding | deleterious(0.05) | probably_damaging(0.992) | TCGA-49-AAR4-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxol | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
253260 | RICTOR | CLINICALLY ACTIONABLE | inhibitor | MLN0128 | SAPANISERTIB | |
253260 | RICTOR | CLINICALLY ACTIONABLE | inhibitor | OSI-027 | OSI-027 | |
253260 | RICTOR | CLINICALLY ACTIONABLE | inhibitor | AZD8055 | AZD-8055 | |
253260 | RICTOR | CLINICALLY ACTIONABLE | VISTUSERTIB | VISTUSERTIB | 28028034 |
Page: 1 |